ResMed (RMD) Expected to Post Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is expected to release its Q4 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $2.89 per share and revenue of $1.4613 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

ResMed Trading Up 2.0%

NYSE RMD opened at $215.12 on Tuesday. The business has a 50 day moving average price of $199.00 and a 200-day moving average price of $223.06. ResMed has a 52 week low of $180.26 and a 52 week high of $293.81. The company has a quick ratio of 2.33, a current ratio of 3.01 and a debt-to-equity ratio of 0.06. The company has a market cap of $31.20 billion, a price-to-earnings ratio of 20.74, a P/E/G ratio of 1.28 and a beta of 0.78.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total value of $1,090,783.05. Following the completion of the transaction, the chief executive officer owned 466,223 shares in the company, valued at $101,893,036.65. This represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 14,973 shares of company stock valued at $3,096,067 over the last 90 days. 0.65% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ResMed

Several institutional investors have recently added to or reduced their stakes in the stock. WFA of San Diego LLC bought a new stake in ResMed in the second quarter worth about $26,000. Imprint Wealth LLC bought a new position in shares of ResMed during the 3rd quarter valued at approximately $26,000. Sunbelt Securities Inc. bought a new position in shares of ResMed during the 3rd quarter valued at approximately $31,000. DV Equities LLC purchased a new stake in shares of ResMed during the 4th quarter worth approximately $49,000. Finally, Kelleher Financial Advisors purchased a new stake in shares of ResMed during the 3rd quarter worth approximately $66,000. Institutional investors own 54.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Jefferies Financial Group dropped their price objective on shares of ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a research note on Friday, July 10th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ResMed in a research report on Wednesday, July 1st. Royal Bank Of Canada downgraded ResMed from an “outperform” rating to a “sector perform” rating and set a $234.00 price target for the company. in a research note on Thursday, July 16th. JPMorgan Chase & Co. initiated coverage on ResMed in a report on Wednesday, April 15th. They set an “overweight” rating for the company. Finally, UBS Group reissued a “buy” rating and issued a $300.00 price objective on shares of ResMed in a research note on Tuesday, July 21st. Seven equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, ResMed currently has a consensus rating of “Hold” and a consensus price target of $246.25.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.